AbbVie Inc. (ABBV34.SA)
| Previous Close | 50.25 |
| Open | 0.00 |
| Bid | 49.00 x 0 |
| Ask | 52.48 x 0 |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 5,750 |
| Market Cap | 1.482T |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | 47.70 |
| EPS (TTM) | 1.09 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | 1.46 (2.81%) |
| Ex-Dividend Date | Apr 12, 2024 |
| 1y Target Est | N/A |
PR NewswireAbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time.
ZacksAbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ZacksGilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
